Your browser doesn't support javascript.
loading
Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective.
Rathod, Reena J; Sukumaran, Reghu K; Kedia, Neelam; Kumar, Jeevan; Nair, Reena; Chandy, Mammen; Gandikota, Lakshmikanth; Radhakrishnan, Vivek Sulekha.
Affiliation
  • Rathod RJ; Cell and Gene Therapy Division, Intas Pharmaceuticals, Ahmedabad, Gujarat, India.
  • Sukumaran RK; Hematology Oncology and HCT, Tata Medical Center, Kolkata, West Bengal, India.
  • Kedia N; Cell and Gene Therapy Division, Intas Pharmaceuticals, Ahmedabad, Gujarat, India.
  • Kumar J; Hematology Oncology and HCT, Tata Medical Center, Kolkata, West Bengal, India.
  • Nair R; Hematology Oncology and HCT, Tata Medical Center, Kolkata, West Bengal, India.
  • Chandy M; Hematology Oncology and HCT, Tata Medical Center, Kolkata, West Bengal, India.
  • Gandikota L; Cell and Gene Therapy Division, Intas Pharmaceuticals, Ahmedabad, Gujarat, India.
  • Radhakrishnan VS; Hematology Oncology and HCT, Tata Medical Center, Kolkata, West Bengal, India.
Indian J Cancer ; 61(2): 204-214, 2024 Apr 01.
Article in En | MEDLINE | ID: mdl-39152647
ABSTRACT
Using one's own immune system for curing cancer has been an active field of research in cancer biology and therapeutics. One such opportunity in cellular immunotherapy is adoptive cell transfers. With the recent approval of CAR-T therapy as a cancer treatment, a whole new paradigm of cancer treatment has opened-up, with a ray of hope for relapsed/refractory cancer patients. Despite promising clinical outcomes, the therapy is in its early phase and remains out of reach for most patients due to its high cost and logistic challenges. In India, these therapies are unavailable and further confounded by the economic challenges and a large population. In this review, we discuss various aspects of T-cell immunotherapies with a special focus on CAR-T in the Indian scenario. We touch upon the basic scientific aspects, mechanism of action, manufacturing, clinical aspects and commercial aspects of the CAR-Tcell therapies and its future worldwide and in India.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy, Adoptive / Receptors, Chimeric Antigen / Neoplasms Limits: Humans Country/Region as subject: Asia Language: En Journal: Indian J Cancer Year: 2024 Document type: Article Affiliation country: India Country of publication: India

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy, Adoptive / Receptors, Chimeric Antigen / Neoplasms Limits: Humans Country/Region as subject: Asia Language: En Journal: Indian J Cancer Year: 2024 Document type: Article Affiliation country: India Country of publication: India